Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment

References

• Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–2078.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416–3423.
   PubMed Web of Science ®Google Scholar
• Delfau-Larue M-H, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604–611.
   PubMed Web of Science ®Google Scholar
• Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110:18250–18255.
   PubMed Web of Science ®Google Scholar
• Meissner B, Kridel R, Lim RS, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood. 2013;121:3161–3164.
   PubMed Web of Science ®Google Scholar
• Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119:4215–4223.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Queirós AC, Beekman R, Vilarrasa-Blasi R, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016;30:806–821.
   PubMed Web of Science ®Google Scholar
• Chiron D, Bellanger C, Papin A, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128:2808–2818.
   PubMed Web of Science ®Google Scholar
• Saba NS, Liu D, Herman SEM, et al. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. 2016;128:82–92.
   PubMed Web of Science ®Google Scholar
• Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71–81.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol. 2011;21:308–312.
   PubMed Web of Science ®Google Scholar
• Corcione A, Arduino N, Ferretti E, et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res. 2004;10:964–971.
   PubMed Web of Science ®Google Scholar
• Ek S, Björck E, Högerkorp C-M, et al. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer. 2006;118:2092–2097.
   PubMed Web of Science ®Google Scholar
• Chang BY, Francesco M, De Rooij MFM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122:2412–2424.
   PubMed Web of Science ®Google Scholar
• Zhang X-Y, Xu J, Zhu H-Y, et al. Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci. 2016;107:1471–1476.
   PubMed Web of Science ®Google Scholar
• Nygren L, Wasik AM, Baumgartner-Wennerholm S, et al. T-cell levels are prognostic in mantle cell lymphoma. Clin Cancer Res. 2014;20:6096–6104.
   PubMed Web of Science ®Google Scholar
• Yang Z-Z, Novak AJ, Stenson MJ, et al. Intratumoral CD4 + CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639–3646.
   PubMed Web of Science ®Google Scholar
• Tomita N, Nakamura N, Ikoma H, et al. Mantle cell lymphoma is associated with a variable number of PD-1-positive tumor infiltrating T-cells. Blood. 2016;128:5317–5317.
   Google Scholar
• Myklebust JH, Irish JM, Brody J, et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013;121:1367–1376.
   PubMed Web of Science ®Google Scholar
• Wang L, Qian J, Lu Y, et al. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica. 2013;98:1458–1466.
   PubMed Web of Science ®Google Scholar
• Castillo R, Mascarenhas J, Telford W, et al. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia. 2000;14:292–298.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Larsen JK, Christiansen J, et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood. 2000;96:2219–2225.
   PubMed Web of Science ®Google Scholar
• Visser HP, Tewis M, Willemze R, et al. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia. 2000;14:1483–1489.
   PubMed Web of Science ®Google Scholar
• Chiron D, Dousset C, Brosseau C, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750–8759.
   PubMed Web of Science ®Google Scholar
• Iyengar S, Ariza-McNaughton L, Clear A, et al. Characteristics of human primary mantle cell lymphoma engraftment in NSG mice. Br J Haematol. 2016;173:165–169.
   PubMed Web of Science ®Google Scholar
• Koh YW, Shin S-J, Park C, et al. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages. Hematol Oncol. 2014;32:178–186.
   PubMed Web of Science ®Google Scholar
• Song K, Herzog BH, Sheng M, et al. Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res. 2013;73:7254–7264.
   PubMed Web of Science ®Google Scholar
• Pham LV, Vang MT, Tamayo AT, et al. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015;56:186–193.
   PubMed Web of Science ®Google Scholar
• Jin MK, Hoster E, Dreyling M, et al. Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome. Histopathology. 2011;58:586–592.
   PubMed Web of Science ®Google Scholar
• Schrader C, Meusers P, Brittinger G, et al. Growth pattern and distribution of follicular dendritic cells in mantle cell lymphoma: a clinicopathological study of 96 patients. Virchows Arch. 2006;448:151–159.
   PubMed Web of Science ®Google Scholar
• Chen Z, Teo AE, McCarty N. ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 2016;22:187–199.
   PubMed Web of Science ®Google Scholar
• Medina DJ, Goodell L, Glod J, et al. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica. 2012;97:1255–1263.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604–4613.
   PubMed Web of Science ®Google Scholar
• Doñate C, Vijaya Kumar A, Imhof BA, et al. Anti-JAM-C therapy eliminates tumor engraftment in a xenograft model of mantle cell lymphoma. J Leukoc Biol. 2016;100:843–853.
   PubMed Web of Science ®Google Scholar
• Chiron D, Di Liberto M, Martin P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022–1035.
   PubMed Web of Science ®Google Scholar
• Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118:3088–3095.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307–5316.
   PubMed Web of Science ®Google Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12:229–243.
   PubMed Web of Science ®Google Scholar
• Myklebust JH, Brody J, Kohrt HE, et al. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood. 2017;129:759–770.
   PubMed Web of Science ®Google Scholar
• Koehrer S, Burger JA. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol. 2016;14:55–65.
   PubMed Web of Science ®Google Scholar
• Hock BD, McKenzie JL, Patton NW, et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer. 2006;106:2148–2157.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Maurer MJ, Stenson MJ, et al. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Am J Hematol. 2014;89:E223–E227.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang J, Qian J, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012;120:3783–3792.
   PubMed Web of Science ®Google Scholar
• Zhang C, Xin H, Zhang W, et al. CD5 binds to interleukin-6 and induces a feed-forward loop with the transcription factor STAT3 in B cells to promote cancer. Immunity. 2016;44:913–923.
   PubMed Web of Science ®Google Scholar
• Bernard S, Danglade D, Gardano L, et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer. 2015;136:2761–2774.
   PubMed Web of Science ®Google Scholar
• Epron G, Ame-Thomas P, Le Priol J, et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia. 2012;26:139–148.
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Pinkus GS. Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23. Mod Pathol. 1994;7:326–331.
   PubMed Web of Science ®Google Scholar
• Baran-Marszak F, Boukhiar M, Harel S, et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010;95:1865–1872.
   PubMed Web of Science ®Google Scholar
• Zhang H, McCarty N. Tampering with cancer chemoresistance by targeting the TGM2-IL6-autophagy regulatory network. Autophagy. 2017;13:627–628.
   PubMed Web of Science ®Google Scholar
• Kim Y-R, Eom K-S. Simultaneous inhibition of CXCR4 and VLA-4 exhibits combinatorial effect in overcoming stroma-mediated chemotherapy resistance in mantle cell lymphoma cells. Immune Netw. 2014;14:296–306.
   PubMedGoogle Scholar
• Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87–92.
   PubMed Web of Science ®Google Scholar
• Fu L, Lin-Lee Y-C, Pham LV, et al. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006;107:4540–4548.
   PubMed Web of Science ®Google Scholar
• Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88–95.
   PubMed Web of Science ®Google Scholar
• Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood. 2001;98:787–794.
   PubMed Web of Science ®Google Scholar
• Katz SG, Labelle JL, Meng H, et al. Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells. Blood. 2014;123:884–893.
   PubMed Web of Science ®Google Scholar
• Lwin T, Lin J, Choi YS, et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 2010;116:5228–5236.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–531.
   PubMed Web of Science ®Google Scholar
• Le Gouill S. Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. San Diego; 2016 [cited 2017 May 2]. Available from: https://ash.confex.com/ash/2016/webprogram/Paper89500.html
   Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–575.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–723.
   PubMed Web of Science ®Google Scholar
• Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica. 2012;97:416–422.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803–2811.
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011;96:1008–1014.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Furtado M, Wang ML, Munneke B, et al. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. Br J Haematol. 2015;170:131–134.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123:1957–1960.
   PubMed Web of Science ®Google Scholar
• Maffei R, Fiorcari S, Martinelli S, et al. Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib. J Hematol Oncol. 2015;8:60.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826–833.
   PubMed Web of Science ®Google Scholar